Autologous transplantation of ex vivo expanded bone marrow cells grown from small aliquots after high-dose chemotherapy for breast cancer

Blood

Volumn 95, Issue 6, 2000, Pages 2169-2174

  Stiff, Patrick ^a   Chen, Bohao ^b   Franklin, Wilbur ^b   Oldenberg, David ^b   Hsi, Eric ^b   Bayer, Robert ^b   Shpall, Elizabeth ^b   Douville, Judy ^b   Mandalam, Ramkumar ^b   Malhotra, Deepak ^b   Muller, Thomas ^b   Armstrong, R Douglas ^b   Smith, Alan ^b  

^a LOYOLA UNIVERSITY HEALTH SYSTEM   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; ERYTHROPOIETIN; FLT3 LIGAND; GRANULOCYTE COLONY STIMULATING FACTOR; MILODISTIM; THIOTEPA;

ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BIOREACTOR; BONE MARROW SUPPRESSION; BREAST CARCINOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER TRANSPLANTATION; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG MEGADOSE; FEMALE; HEMATOPOIESIS; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; TREATMENT OUTCOME;

EID: 0034654025     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.6.2169     Document Type: Article

References (54)

1. Bortin MM, Buckner CD. Major complications of marrow harvesting for transplantation. Exp Hematol. 1993;11:916-921.
2. Klumpp TR. Complications of peripheral blood stem cell transplantation. Semin Oncol. 1995;22: 263-270.
3. Johnston CS, Shpall ES, Williams S, et al. Detection of minimal residual breast cancer in bone marrow. Prog Clin Biol Res. 1992;377:637-642.
4. Brenner M, Rill D, Moen R, et al. Gene-marking to trace origin of relapse after autologous bone marrow transplantation. Lancet. 1993;341: 85-86.
5. Moss TJ, Umiel T, Herzig RH, et al. The presence of clonogenic breast cancer cells in peripheral blood stem cell (PBPC) products correlates with an extremely poor prognosis for patients with Stage IV disease [abstract]. Proc Am Soc Clin Oncol. 1998;17:106a.
6. Dexter TM, Allen TD, Lagtha LG. Conditions controlling the proliferation of hematopoietic stem cells in vitro. J Cell Physiol. 1977;91:335-344.
7. Gartner S, Kaplan MS. Long-term culture of human bone marrow cells. Proc Natl Acad Sci U S A. 1980;74:4656-4660.
8. Schwartz R, Emerson SG, Clarke MF, Palsson BO. In vitro myelopoiesis stimulated by rapid medium exchange and supplemented with hematopoietic growth factors. Blood. 1991;78:3155-3161.
9. Koller MR, Emerson SG, Palsson BO. Large scale expansion of human hematopoietic stem and progenitor cells for bone marrow mono nuclear cells in continuous perfusion culture. Blood. 1993;82:378-384.
10. Koller MR, Palsson MA, Manchel I, Palsson BO. LTCIC expansion is dependent on frequent median exchange combined with stromal and other accessory cell effects. Blood. 1995;86:1784-1793.
11. Koller MR, Manchel I, Brott DA, et al. Donor-to-donor variability in the expansion potential of human bone marrow cells is reduced by accessory cells but not by soluble growth factors. Exp Hematol. 1996;24:1484-1493.
12. Koller MR, Manchel I, Newsome BS, Pallson MA, Palsson BO. Bioreactor expansion of human bone marrow: comparison of unprocessed, density-separated, and CD34-enriched cells. J Hematother. 1995;4:159-169.
13. Koller MR, Bradley MS, Palsson BO. Growth factor consumption and production in perfusion cultures of human bone marrow correlate with specific cell production. Exp Hematol. 1995;23: 1275-1283.
14. Zandstra PW, Eaves CJ, Cameron C, Piret JM. Cytokine depletion in long-term stirred suspension cultures of normal human marrow [abstract]. J Hematother. 1995;4:235.
15. Muench MO, Firpo MT, Moore MAS. Bone marrow transplantation with interleukin-1 plus kit-ligand ex vivo expanded bone marrow accelerates hematopoietic reconstitution in mice without the loss of stem cell lineage and proliferative potential. Blood. 1993;81:3463-3473.
16. Palsson BO, Paek SH, Schwartz, RM, et al. Expansion of human bone marrow progenitor cells in a high cell density continuous perfusion system. Biotechnology. 1993;11:368-373.
17. Silver SM, Adams PT, Hutchinson RJ, et al. Phase I evaluation of ex vivo expanded hematopoietic cells produced by perfusion culture in autologous bone marrow transplantation (ABMT) [abstract]. Blood. 1993;82:297a.
18. Lundell BI Tyer C, DeSombre K, Vredenburgh JJ, Smith AK. Ex vivo perfusion culture expansion of tumor positive bone marrow from breast cancer patients results in passive purging during the culture period. Bone Marrow Transplant. 1998;22: 153-159.
19. Thomas ED, Storb R. Technique for human marrow grafting. Blood. 1970;36:507-515.
20. Franklin WA, Shpall EJ, Archer P, et al. Immunocytochemical detection of breast cancer cells in marrow and peripheral blood of patients undergoing high dose chemotherapy with autologous support. Breast Cancer Res Treat. 1996;41:1-13.
21. Antman K, Ayash L, Elias A, et al. A phase II study of high dose cyclophosphamide, thiotepa and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard dose therapy. J Clin Oncol. 1992;10:102-110.
22. O'Dwyer PJ, LaCreta F, Engstrom PF, et al. Phase I/pharmacokinetic re-evaluation of thiotepa. Cancer Res. 1991;51:3171-3176.
23. Wolff SN, Herzig RH, Fay JW, et al. High-dose N, N', N"-triethylene-thiophosphamide (thiotepa) with autologous bone marrow transplantation: phase I studies. Semin Oncol. 1990;17(suppl 3): 2-6.
24. Schmitz N. Linch DC, Dreger P, et al. Randomized trial of filgrastim-mobilized peripheral blood progenitor cell transplantation versus autologous bone marrow transplantation in lymphoma patients. Lancet. 1996;347:353-357.
25. Holland HK, Dix SP, Geller RB, et al. Minimal toxicity and mortality in high risk breast cancer patients receiving high dose cyclophosphamide, thiotepa and carboplatin plus autologous marrow/ stem cell transplantation and comprehensive supportive care. J Clin Oncol. 1996;14:1156-1164.
26. Bensinger W, Appelbaum F, Rowley S, et al. Factors that influence collection and engraftment of autologous peripheral blood stem cells. J Clin Oncol. 1995;13:2547-2555.
27. Glaspy JA, Shpall EJ, LeMaistre CF, et al. Peripheral blood progenitor cell mobilization using stem cell factor in combination with filgrastim in breast cancer patients. Blood. 1997;90:2939-2951.
28. Perez-Simon JA, Caballeo MD, Corral M, et al. Minimal number of circulating CD34+ cells to ensure successful leukapheresis and engraftment in autologous peripheral blood progenitor cell transplantation. Transfusion. 1998;38:385-391.
29. Perez-Simon JA, Martin A, Calalleo D, et al. CD34+ cell dose in autologous transplantation: relationship with long term engraftment and late complications [abstract]. Bone Marrow Transplant. 1999;23(suppl 1):S208.
30. Watts MJ, Sullivan AM, Leverett D, et al. Back-up bone marrow is frequently ineffective in patients with poor peripheral-blood stem-cell mobilization. J Clin Oncol. 1998;16:1554-1560.
31. Calvo W, Fleidner TM, Herbst E, et al. Regeneration of blood forming organs after autologous leukocyte transfusion in lethally irradiated dogs. II. Distribution and cellularity of the marrow in irradiated and transfused animals. Blood. 1975;47: 593-597.
32. Appelbaum FR, Herzig GP, Graw RG, et al. Study of cell dose and storage time on engraftment of cryopreserved autologous bone marrow in a canine mode. Transplantation. 1978;26:245-248.
33. Yaroslavskiy B, Colson Y, Ildstad S, Parrish D, Boggs SS. Addition of a bone marrow "facilitating cell" population increases stem cell-derived cobblestone area formation in impaired long-term bone marrow culture stroma. Exp Hematol. 1998; 26:604-611.
34. Breems DA, Blokland EA, Siebel KE, Mayen AE, Engels LJ, Ploemacher RE. Stroma-contact prevents loss of hematopoietic stem cell quality during ex vivo expansion of CD34+ mobilized peripheral blood stem cells. Blood. 1998;91:111-117.
35. Castro-Malaspina H, Gay RE, Resnick G, et al. Characterization of human bone marrow fibroblast colony-forming cells (CFU-F) and their progeny. Blood. 1980;56:289-301.
36. Anklesaria P, Kase K, Glowacki J, Holland CA, Sakakeeny MA, Wright JA. Engraftment of a clonal bone marrow stromal cell line in vivo stimulates hematopoietic recovery from total body irradiation. Proc Natl Acad Sci U S A. 1987;84:7681-7685.
37. delCanizo MC, Lopez N, Vazquez I, et al. Hematopoietic damage prior to PBSCT and its influence on hematopoietic recovery. Hematologica. 1999;84:511-516.
38. Gibson LF, Fortney J, Landreth KS, Piktel D, Ericson SG, Lynch JP. Disruption of bone marrow stromal cell function by etoposide. Biol Blood Marrow Transplant. 1997;3:122-132.
39. Carlo-Stella C, Tabilio A, Regazzi E, et al. Effect of chemotherapy for acute myeloid leukemia on hematopoietic and fibroblast marrow progenitors. Bone Marrow Transplant. 1997;20:465-471.
40. Soligo DA, Lambetenghi DG, Servida F, et al. Hematopoietic abnormalities after autologous stem cell transplantation in lymphoma patients. Bone Marrow Transplant. 1998;21:15-22.
41. Galotto M, Berisso G, Delfino L, et al. Stromal damage as consequence of high-dose chemo/ radiotherapy in bone marrow transplant recipients. Exp Hematol. 1999;27:1460-1466.
42. Chute JP, Saini AA, Kampen RL, Wells MR, Davis TA. A comparative study of the cell cycle status and primitive cell adhesion molecule profile of human CD34+ cells cultured in stroma-free versus porcine microvascular endothelial cell cultures. Exp Hematol. 1999;27:370-379.
43. Lazarus HM, Haynesworth SE, Gerson SL, Rosenthal NS, Caplan AI. Ex vivo expansion and subsequent infusion of human bone marrow derived stromal progenitor cells (mesenchymal progenitor cells) [MPCs]: implications for therapeutic use. Bone Marrow Transplant. 1995;16:557-564.
44. Lazarus HM, Haynesworth SE, Gerson SL, Caplan AI. Clinical trials using human bone marrow derived mesenchymal (stromal) progenitor cells. In: Keating A, Greenberger J, eds. Bone Marrow Microenvironment and Hematopoiesis. Humana Press. In press.
45. Brugger W, Heimfeld S, Berenson RJ, Mertelsman R, Kong L. Reconstitution of hematopoiesis after high-dose chemotherapy by autologous progenitor cells generated ex vivo. New Engl J Med. 1995;333:283-287.
46. Holyoake L, Alcorn MJ, Richmond L, et al. CD34 positive PBPC expanded ex vivo may not provide durable engraftment following myeloablative chemoradiotherapy regimens. Bone Marrow Transplant. 1997;19:1095-1101.
47. Williams SF, Lee WJ, Bender JG, et al. Selection and expansion of peripheral blood CD34+ cells in autologous stem cell transplantation for breast cancer. Blood. 1996;57:1687-1691.
48. Reiffers J, Calliot C, Dozey B, et al. Infusion of expanded CD34+ selected cells can abrogate post myeloablative chemotherapy neutropenia in patients with hematologic malignancies [abstract]. Blood. 1998;92(suppl 1):126a.
49. Petzer AL, Hogge DE, Landsdorp PM, Reid DS, Eaves CJ. Self-renewal of primitive human hematopoietic cells (long-term-culture-initiating cells) in vitro and their expansion in defined media. Proc Natl Acad Sci U S A. 1996;93:1470-1474.
50. Mandalam RK, Vento CA, Brott DA, Smith AK. Synergistic effects of thrombopoietin, SCF and flt3-1 in ex vivo expansion cultures [abstract]. Exp Hematol. 1998;26:768.
51. Mandalam RK, Vento CA, Stiff PJ, Brott DA, Smith AK. Stem and progenitor cell content and ex vivo expansion potential of human bone marrow primed in vivo with G-CSF [abstract]. Blood. 1997;90:344b.
52. Stiff P, Parthasarathy M, Chen B, et al. A single apheresis combined with ex vivo expanded bone marrow cells from a small starting aliquot leads to rapid hematopoietic engraftment following autotransplantation [abstract]. Blood. 1998;92 (suppl 1):132.
53. Goltry KL, Koller MR, Maher R, et al. Clinical-scale expansion of human umbilical cord blood cells in an automated perfused culture system. Bone Marrow Transplant. 1998;21:653-663.
54. Mandalam RK, Douville J, Stiff PJ, et al. An alternative stem cell transplant source for poor mobilizers: ex vivo expanded bone marrow cells [abstract]. Cytotherapy. 1999;1:243.